Max Healthcare Institute Dirección

Dirección controles de criterios 2/4

El CEO de Max Healthcare Institute es Abhay Soi , nombrado en Jun 2020, tiene una permanencia de 4.42 años. compensación anual total es ₹247.33M, compuesta por 79.7% salario y 20.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 23.74% de las acciones de la empresa, por valor de ₹227.58B. La antigüedad media del equipo directivo y de la junta directiva es de 5.1 años y 3.5 años, respectivamente.

Información clave

Abhay Soi

Chief Executive Officer (CEO)

₹247.3m

Compensación total

Porcentaje del salario del CEO	79.7%
Permanencia del CEO	4.4yrs
Participación del CEO	23.7%
Permanencia media de la dirección	5.1yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Abhay Soi en comparación con los beneficios de Max Healthcare Institute?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	₹11b
Jun 30 2024	n/a	n/a	₹11b
Mar 31 2024	₹247m	₹197m	₹11b
Dec 31 2023	n/a	n/a	₹11b
Sep 30 2023	n/a	n/a	₹10b
Jun 30 2023	n/a	n/a	₹12b
Mar 31 2023	₹140m	₹140m	₹11b
Dec 31 2022	n/a	n/a	₹10b
Sep 30 2022	n/a	n/a	₹9b
Jun 30 2022	n/a	n/a	₹6b
Mar 31 2022	₹140m	₹49m	₹6b
Dec 31 2021	n/a	n/a	₹6b
Sep 30 2021	n/a	n/a	₹5b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹117m	₹91m	-₹1b

Compensación vs. Mercado: La compensación total de Abhay($USD2.93M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD1.08M).

Compensación vs. Ingresos: La compensación de Abhay ha aumentado más de un 20% en el último año.

CEO

Abhay Soi (51 yo)

4.4yrs

Permanencia

₹247,330,308

Compensación

Mr. Abhay Soi is a Co-Founder of Halcyon Group. He served as Executive Officer at Ernst & Young LLP. Mr. Soi served as Head of Financial Restructuring group at Ernst & Young and Arthur Anderson.He has in-...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Abhay Soi	Chairman & MD	4.4yrs	₹247.33m	23.74% ₹ 227.6b
Yogesh Sareen	Senior Director & CFO	12.8yrs	₹45.10m	0.0062% ₹ 59.1m
Dhiraj Aroraa	Senior VP	1.8yrs	₹10.00m	sin datos
Mradul Kaushik	Member of Group Medical Advisory Council	no data	sin datos	sin datos
Prashant Singh	Director of Information Technology & Chief Information Officer	5.2yrs	sin datos	sin datos
Gagan Palta	General Counsel & Director	less than a year	sin datos	sin datos
Anas Wajid	Senior Director and Chief Sales & Marketing Officer	no data	sin datos	sin datos
Umesh Gupta	Member of Group Medical Advisory Council	5.3yrs	sin datos	sin datos
Sandeep Budhiraja	Member of Group Medical Advisory Council & Group Medical Director	no data	sin datos	sin datos
Sanjiv K. Marya	Member of Group Medical Advisory Council	5.1yrs	sin datos	sin datos
Anurag Krishna	Chairman of Paediatrics & Paediatric Surgery	3.8yrs	sin datos	sin datos
Harinder Chehal	Senior Director & COO - Cluster 2	5.3yrs	sin datos	sin datos

5.1yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 543220 es experimentado (5.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Abhay Soi	Chairman & MD	5.4yrs	₹247.33m	23.74% ₹ 227.6b
Mradul Kaushik	Member of Group Medical Advisory Council	no data	sin datos	sin datos
Gagan Palta	General Counsel & Director	less than a year	sin datos	sin datos
Umesh Gupta	Member of Group Medical Advisory Council	no data	sin datos	sin datos
Sandeep Budhiraja	Member of Group Medical Advisory Council & Group Medical Director	no data	sin datos	sin datos
Sanjiv K. Marya	Member of Group Medical Advisory Council	no data	sin datos	sin datos
N. Venkatesan	Director & Chief Procurement Officer	no data	sin datos	sin datos
Mahendra Lodha	Non-Executive Independent Director	5.4yrs	₹5.25m	sin datos
Narayan Seshadri	Non-Executive Non-Independent Director	1.5yrs	₹3.83m	sin datos
Pradeep Chowbey	Member of Group Medical Advisory Council	no data	₹4.42m	sin datos
Harit Chaturvedi	Member of Group Medical Advisory Council	no data	sin datos	sin datos
Dinesh Khullar	Member of Group Medical Advisory Council	no data	sin datos	sin datos

3.5yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 543220 se considera experimentada (3.5 años de antigüedad promedio).

Max Healthcare Institute Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Max Healthcare Institute Limited Cessation of Gautam Wadhwa as Director

Max Healthcare Institute Limited Appoints Kummamuri Narasimha Murthy as an Independent Director

Insufficient new directors

Max Healthcare Institute Limited, Annual General Meeting, Sep 20, 2024

Max Healthcare Institute Limited Announces Change in Management

Max Healthcare Institute Limited, Annual General Meeting, Sep 27, 2023

Recent updates

Consensus revenue estimates increase by 13%

Max Healthcare Institute Limited (BSE:543220) acquired remaining 36.35% stake in Jaypee Healthcare Limited from Lakshdeep Investments & Finance Pvt. Ltd and Lakshdeep Infrastructure and Holding Private Limited for INR 2.3 billion.

Price target increased by 8.2% to ₹1,017

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited Cessation of Gautam Wadhwa as Director

Max Healthcare Institute Limited (BSE:543220) completed the acquisition of 63.65% stake in Jaypee Healthcare Limited from Lakshdeep Investments & Finance Pvt. Ltd and Lakshdeep Infrastructure and Holding Private Limited for INR 4 billion.

Max Healthcare Institute Limited Appoints Kummamuri Narasimha Murthy as an Independent Director

Max Healthcare Institute Limited Announces Declaration of Final Dividend

Max Healthcare Institute Limited (BSE:543220) entered into a Strategic Collaboration Agreement to acquire 64% stake in Jaypee Healthcare Limited from Lakshdeep Investments & Finance Pvt. Ltd and Lakshdeep Infrastructure and Holding Private Limited for an enterprise value of INR 16.6 billion.

Insufficient new directors

Max Healthcare Institute Limited to Report Q2, 2025 Results on Nov 06, 2024

Upcoming dividend of ₹1.50 per share

Max Healthcare Institute Limited, Annual General Meeting, Sep 20, 2024

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q1, 2025 Results on Aug 01, 2024

Max Healthcare Institute Limited Recommends Final Dividend for the Financial Year 2023-24

Full year 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q4, 2024 Results on May 22, 2024

Max Healthcare Institute Limited (BSE:543220) agreed to acquire Alexis Multi-speciality Hospital Private Limited for approximately INR 3720 million.

Price target increased by 11% to ₹767

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Nine Months, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q2, 2024 Results on Nov 06, 2023

Max Healthcare Institute Limited Approves the Declaration of Final Dividend for the Financial Year Ended March 31, 2023

Max Healthcare Institute Limited Announces Change in Management

Max Healthcare Institute Limited Provides Update on Petition Filed by the Company Against Touch Healthcare Private Limited and Others

Max Healthcare Institute Limited, Annual General Meeting, Sep 27, 2023

Max Healthcare Institute Limited Announces Appointment of Amrita Gangotra as Additional Director (Non-Executive and Independent Woman Director)

Price target increased by 7.1% to ₹611

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q1, 2024 Results on Aug 07, 2023

Aster Eye $300 million India Stake Sale

Price target increased by 8.1% to ₹564

Full year 2023 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited to Report Q4, 2023 Results on May 16, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 12%

Max Healthcare Institute Limited Announces Executive Changes

Max Healthcare Institute Limited to Report Q3, 2023 Results on Feb 02, 2023

Blackstone, CVC Manipal, Max Reportedly Eye KIMS Stake

Max Healthcare Reportedly Eyeing AMRI Hospitals

Price target increased to ₹512

Price target increased to ₹498

KKR, Temasek Reportedly Vie for Care Hospitals; Deal Likely at $1 Billion

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Max Healthcare Institute Limited Announces Management Changes

Max Healthcare Institute Limited to Report Q2, 2023 Results on Nov 01, 2022

Max Healthcare Institute Limited Announces Resignation of Ruchi Mahajan as Company Secretary and Compliance Officer

Max Healthcare Institute Limited Announces Cessation of Prashant Kumar as Non-Executive Non-Independent Director

Investor sentiment improved over the past week

Max Healthcare Institute Limited Announces Resignation of Gaurav Trehan as Non-Executive Non-Independent Director

KKR Reportedly Plans to Exit Max Healthcare by Selling its Entire 27.54% Stake

Max Healthcare Institute Limited, Annual General Meeting, Sep 26, 2022

High number of new directors

Max Healthcare Institute Limited to Report Q1, 2023 Results on Aug 10, 2022

KKR Affiliate Not in Talks for Stake Sale in Max Health

KKR Reportedly May Sell Stake in Max

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ontario Teachers' Pension Plan Board, Max Healthcare Reportedly Lead the Race for Sahyadri Hospitals

Ontario Teachers' Pension Plan Board, Max Healthcare Reportedly Lead the Race for Sahyadri Hospitals

Max Healthcare Institute Limited to Report Q4, 2022 Results on May 25, 2022

High number of new and inexperienced directors

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Max Healthcare Institute Limited Announces Executive Changes

Max Healthcare Institute Limited to Report Q3, 2022 Results on Feb 12, 2022

Consensus forecasts updated

Price target increased to ₹444